Varenicline: no link with cardiovascular events found in meta-analysis

Varenicline (Champix) is a partial agonist to nicotine receptors, and is approved for smoking cessation therapy. However, the FDA has raised concern about a possible increase in the incidence of cardiovascular events of patients taking the drug in randomised trials. In this meta-analysis, Prochaska et al. looked at 22 randomised controlled trials of current tobacco […]

Read More…

FOCUS-CCTRN: Autologous bone marrow cells fail to improve heart failure

Autologous stem/progenitor cells have been investigated for several years as a novel therapy for patients with advanced ischaemic heart disease, particularly those with ongoing angina or heart failure.  In particular, for patients with ischaemic cardiomyopathy, autologous bone marrow mononuclear cells (BMCs) have been shown to be safe and possibly effective.  However, none of the trials […]

Read More…

Infective endocarditis caused by cardiac devices

The number of electronic cardiac devices, including pacemakers and cardioverter-defibrillators, being implanted each year is increasing.  As a result, there has been a 210% increase in the incidence of device infection between 1993 and 2008 in the United States.  Cardiac device infective endocarditis (CDIE) is significant in that it is associated with a higher mortality […]

Read More…

7 ‘Heart Healthy’ Factors Reduce Risk of Death

In recent years an increasing emphasis has been placed on the need for improved primary prevention of cardiovascular disease.  To this end, using evidence from clinical trials and epidemiological studies, the American Heart Association (AHA) has suggested seven ideal cardiovascular health behaviours (metrics), including: not smoking; being physically active; having normal blood pressure, blood glucose and […]

Read More…

2-year PARTNER data published

While the last 5 years have seen an incredible expansion in the use of transcatheter aortic-vlave replacement (TAVR) for patients with severe aortic stenosis who are not considered suitable for surgery, long-term outcomes data remain scant.  The randomised Placement of Aortic Transcatheter Valves (PARTNER) trial found that, as compared with standard therapy, TAVR reduced symptoms […]

Read More…

Epinephrine Use and Cardiac Arrest Survival

Whist epinephrine (adrenaline) is commonly used during cardiopulmonary resuscitation (CPR), both in and out of hospital, its effectiveness is poorly established.  Although some animal studies have suggested a short term benefit due to increased cerebral and coronary perfusion, an increase in myocardial oxygen consumption and ventricular arrhythmias has also been documented.  The purpose of this […]

Read More…

PFO and stroke – to close or not to close?

Approximately 40% of strokes are classified as cryptogenic or as having no identifiable cause.  Some of these cryptogenic strokes may be due to an embolus from the venous circulation crossing into the systemic circulation through a patent foramen ovale (PFO).  While PFOs are certainly common in the general population – with a prevalence of around […]

Read More…

EuroSCORE updated

The European System for Cardiac Operative Risk Evaluation (EuroSCORE) is one of the most widely used cardiac risk models for predicting mortality after cardiac surgery and forms the basis of many pre-operative discussions surrounding risk/benefit ratios and gaining informed consent for a procedure.  First published in 1999 and derived from an international European database, the […]

Read More…